Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1

A composition, a technology of cartilage tissue, applied in the field of compositions for diseases or symptoms, compositions for improving or treating dwarfism, compositions for improving or treating osteoarthritis, prevention, and compositions for regenerating cartilage, capable of solving problems without Specific mention of prevention, improvement or treatment, etc., to achieve the effect of small side effects and promoting bone growth

Pending Publication Date: 2021-10-08
HAPLNSCI INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no specific mention in the above documents of using HAPLN1 to prevent, improve or treat cartilage-related diseases or symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1
  • Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1
  • Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1: Analysis of cartilage regeneration ability of HAPLN1 protein in degenerated cartilage tissue in vivo

[0056] 1-1. Promotion of cartilage formation in degenerated growth plate by repeated intraperitoneal administration of HAPLN1 protein

[0057] The 6-week-old male C57BL / 6 mice were classified into the young (Young) group, and the 20-month-old C57BL / 6 mice were classified into the aging (Old) group. In the aging group, the HAPLN1 protein was diluted in phosphoric acid Buffered saline (phosphate buffered saline: PBS) was intraperitoneally administered at a dose of 0.1 mg / kg for 2 weeks, and the control group was intraperitoneally administered PBS in the same manner.

[0058] Take the femur and knee joints of mice in each group, and fix them with neutral buffered 10% formalin (NBF) for 48 hours, and then use 10% ethylenediaminetetraacetic acid (EDTA) sequentially The solution was decalcified for 7 days. Subsequently, each specimen was embedded in paraffin t...

Embodiment 2

[0064] Example 2: Analysis of cartilage regeneration ability of HAPLN1 protein in damaged cartilage tissue in vivo

[0065] Seven-week-old male C57BL / 6 mice were divided into the following three groups. The normal control group (sham operation control group) was a simulated operation group (shamoperation) regarding destabilization of medial meniscus (DMM) operation, and they were raised under the existing conditions for 4 weeks after the operation. In the vehicle (Vehicle) treatment group (DMM control group), they were raised under the existing conditions for 8 weeks after the DMM operation, and PBS was intra-articularly administered once a week for the last 4 weeks. In the HAPLN1 treatment group (DMM HAPLN1 group), they were raised under the existing conditions for 8 weeks after the DMM operation, and the HAPLN1 protein was diluted in PBS at a concentration of 1 μg / mL once a week for the last 4 weeks and joints were performed. Administered internally.

[0066] At the end of...

Embodiment 3

[0069] Example 3: Analysis of the ability of HAPLN1 protein to promote cartilage formation in vitro

[0070] 3-1. HAPLN1 protein increases the cartilage formation ability of human articular chondrocytes

[0071] Human articular chondrocytes (human articular chondrocyte: HAC) contained 10% fetal bovine serum (fetal bovine serum; FBS; Gibco), 1% penicillin / streptomycin (Gibco) and 1% non-essential Amino acid (non-essential amino acid; NEAA; Gibco) DMEM (Dulbecco's modified Eagle medium) medium and F12 mixed in a 1:1 (DMEM / F12; Gibco) medium at 37 ° C and 5% CO 2 cultured under conditions.

[0072] As a model for testing the chondrogenic ability of HAC, a three-dimensional culture system in which cells were embedded in alginate beads was used. The HAC was uniformly mixed in a 1.25% alginate solution, and each bead contained 30,000 cells. They were prepared by adding 50 μg / mL L-ascorbic acid 2-phosphate, 1% insulin-transferrin-selenium (ITS; Gibco) and 10 ng / mL TGF-β1 to the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hyaluronan and proteoglycan link protein 1 (HAPLN1) as an active ingredient. Specifically, the present invention provides a composition for regenerating cartilage, a composition for preventing, relieving or treating osteoarthritis or a composition for regenerating growth plate cartilage, which comprise HAPLN1 as an active ingredient.

Description

technical field [0001] The present invention relates to a composition for preventing, improving or treating diseases or symptoms related to cartilage, comprising hyaluronan and proteoglycan link protein 1 (HAPLN1) as an active ingredient. Specifically, the present invention relates to a composition for regenerating cartilage or a composition for preventing, improving or treating osteoarthritis, which includes HAPLN1 as an active ingredient. Alternatively, the present invention relates to a composition for proliferating growth plate cartilage or promoting bone growth, or a composition for preventing, improving or treating shortstature. Background technique [0002] Osteoarthritis is a degenerative joint disease that stimulates patients with joint pain, joint swelling and reduced range of motion, and leads to the destruction of articular cartilage and major bones. Osteoarthritis is known to affect at least 1 in 10 adults (Lawrence, Felson et al., 2008), leading to a greatly r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/728A61K38/14A23L33/10
CPCA23L33/10A61K31/728A61P19/02A61P19/08A61P19/04A61K38/17A61P19/00A61K2300/00A23K20/147A23L33/17A61K38/1709
Inventor 金大敬张智旻
Owner HAPLNSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap